The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.
 
Paul Nghiem
Leadership - Society for Investigative Dermatology (SID)
Honoraria - UpToDate; UpToDate
Consulting or Advisory Role - 4SC; EMD Serono; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb; EMD Serono
Patents, Royalties, Other Intellectual Property - Patent filed: "Merkel cell polyomavirus T antigen-specific TCRs and uses thereof" (Inst); Patent pending for high affinity T cell receptors that target the Merkel polyomavirus.
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Sanofi/Regeneron
 
Shailender Bhatia
Stock and Other Ownership Interests - Moderna Therapeutics
Honoraria - Bristol-Myers Squibb; EMD Serono; EMD Serono; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; EMD Serono; Exicure; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exicure (Inst); Immune Design (Inst); Incyte (Inst); Merck (Inst); NantWorks (Inst); Nektar (Inst); Novartis (Inst); OncoSec (Inst)
Travel, Accommodations, Expenses - NantWorks; Sanofi/Regeneron
 
Andrew S. Brohl
Consulting or Advisory Role - Bayer; Deciphera; EMD Serono
Expert Testimony - GlaxoSmithKline (I)
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Janice M. Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Sanofi/Regeneron; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
 
Patrick Terheyden
Honoraria - Bristol-Myers Squibb; CureVac; Merck Serono; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Kent C. Shih
No Relationships to Disclose
 
Isaac Brownell
No Relationships to Disclose
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Other Relationship - Avantis Medical Systems
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Gerald P. Linette
No Relationships to Disclose
 
Michele Milella
Consulting or Advisory Role - Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Huiling Xiong
No Relationships to Disclose
 
Guelseren Guezel
Employment - Merck KGaA
 
Sandra P. D'Angelo
Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Immunocore; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar